Report Detail

Pharma & Healthcare Global Flu RNA Vaccines Market Research Report 2022

  • RnM4438739
  • |
  • 11 May, 2022
  • |
  • Global
  • |
  • 92 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Summary:

The major advantage of Flu RNA Vaccines is that scientist need not to use the live cells for the vaccine preparation as such the RNA can be produced in the laboratory from a DNA template using readily available materials which can be a easy and fast weapon to fight against the new outbreaks and the existing infectious diseases.
Industry Insights
Due to the COVID-19 pandemic, the global Flu RNA Vaccines market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Flu RNA Vaccines market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Flu RNA Vaccines landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Non-Replicating mRNA accounting for % of the Flu RNA Vaccines global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Flu RNA Vaccines include Sanofi Pasteur Inc., AstraZeneca, CSL Ltd., Abbott, GlaxoSmithKline Plc., Serum Institute of India Pvt. Ltd., Pfizer, BioNTech and F.Hoffman La Roche Ltd, etc. In terms of revenue, the global 3 largest players have a % market share of Flu RNA Vaccines in 2021.
This report focuses on Flu RNA Vaccines volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Flu RNA Vaccines market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Post-covid-19 Outlook
The readers in the section will understand how the Flu RNA Vaccines market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Segmental Outlook
Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).
Segment by Type
Non-Replicating mRNA
In Vivo Self-Replicating mRNA
In Vitro Dendritic Cell Non-Replicating mRNA Vaccine
Others
Segment by Application
Hospitals
Vaccination Center
Specialized Clinics
Hospital Pharmacy
Others
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Competitive Scenario
In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Sanofi Pasteur Inc.
AstraZeneca
CSL Ltd.
Abbott
GlaxoSmithKline Plc.
Serum Institute of India Pvt. Ltd.
Pfizer
BioNTech
F.Hoffman La Roche Ltd
Novartis
Sinnovac Biotech Ltd
Moderna Therapeutics
CureVac
Frequently Asked Questions
Which product segment grabbed the largest share in the Flu RNA Vaccines market?
How is the competitive scenario of the Flu RNA Vaccines market?
Which are the key factors aiding the Flu RNA Vaccines market growth?
Which are the prominent players in the Flu RNA Vaccines market?
Which region holds the maximum share in the Flu RNA Vaccines market?
What will be the CAGR of the Flu RNA Vaccines market during the forecast period?
Which application segment emerged as the leading segment in the Flu RNA Vaccines market?
What key trends are likely to emerge in the Flu RNA Vaccines market in the coming years?
What will be the Flu RNA Vaccines market size by 2028?
Which company held the largest share in the Flu RNA Vaccines market?


Table of Contents

    1 Flu RNA Vaccines Market Overview

    • 1.1 Product Overview and Scope of Flu RNA Vaccines
    • 1.2 Flu RNA Vaccines Segment by Type
      • 1.2.1 Global Flu RNA Vaccines Sales Growth Rate Comparison by Type (2022-2028)
      • 1.2.2 Non-Replicating mRNA
      • 1.2.3 In Vivo Self-Replicating mRNA
      • 1.2.4 In Vitro Dendritic Cell Non-Replicating mRNA Vaccine
      • 1.2.5 Others
    • 1.3 Flu RNA Vaccines Segment by Application
      • 1.3.1 Global Flu RNA Vaccines Sales Comparison by Application: (2022-2028)
      • 1.3.2 Hospitals
      • 1.3.3 Vaccination Center
      • 1.3.4 Specialized Clinics
      • 1.3.5 Hospital Pharmacy
      • 1.3.6 Others
    • 1.4 Global Flu RNA Vaccines Market Size Estimates and Forecasts
      • 1.4.1 Global Flu RNA Vaccines Revenue 2017-2028
      • 1.4.2 Global Flu RNA Vaccines Sales 2017-2028
      • 1.4.3 Flu RNA Vaccines Market Size by Region: 2017 Versus 2021 Versus 2028

    2 Flu RNA Vaccines Market Competition by Manufacturers

    • 2.1 Global Flu RNA Vaccines Sales Market Share by Manufacturers (2017-2022)
    • 2.2 Global Flu RNA Vaccines Revenue Market Share by Manufacturers (2017-2022)
    • 2.3 Global Flu RNA Vaccines Average Price by Manufacturers (2017-2022)
    • 2.4 Manufacturers Flu RNA Vaccines Manufacturing Sites, Area Served, Product Type
    • 2.5 Flu RNA Vaccines Market Competitive Situation and Trends
      • 2.5.1 Flu RNA Vaccines Market Concentration Rate
      • 2.5.2 The Global Top 5 and Top 10 Largest Flu RNA Vaccines Players Market Share by Revenue
      • 2.5.3 Global Flu RNA Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

    3 Flu RNA Vaccines Retrospective Market Scenario by Region

    • 3.1 Global Flu RNA Vaccines Retrospective Market Scenario in Sales by Region: 2017-2022
    • 3.2 Global Flu RNA Vaccines Retrospective Market Scenario in Revenue by Region: 2017-2022
    • 3.3 North America Flu RNA Vaccines Market Facts & Figures by Country
      • 3.3.1 North America Flu RNA Vaccines Sales by Country
      • 3.3.2 North America Flu RNA Vaccines Revenue by Country
      • 3.3.3 United States
      • 3.3.4 Canada
    • 3.4 Europe Flu RNA Vaccines Market Facts & Figures by Country
      • 3.4.1 Europe Flu RNA Vaccines Sales by Country
      • 3.4.2 Europe Flu RNA Vaccines Revenue by Country
      • 3.4.3 Germany
      • 3.4.4 France
      • 3.4.5 U.K.
      • 3.4.6 Italy
      • 3.4.7 Russia
    • 3.5 Asia Pacific Flu RNA Vaccines Market Facts & Figures by Region
      • 3.5.1 Asia Pacific Flu RNA Vaccines Sales by Region
      • 3.5.2 Asia Pacific Flu RNA Vaccines Revenue by Region
      • 3.5.3 China
      • 3.5.4 Japan
      • 3.5.5 South Korea
      • 3.5.6 India
      • 3.5.7 Australia
      • 3.5.8 China Taiwan
      • 3.5.9 Indonesia
      • 3.5.10 Thailand
      • 3.5.11 Malaysia
    • 3.6 Latin America Flu RNA Vaccines Market Facts & Figures by Country
      • 3.6.1 Latin America Flu RNA Vaccines Sales by Country
      • 3.6.2 Latin America Flu RNA Vaccines Revenue by Country
      • 3.6.3 Mexico
      • 3.6.4 Brazil
      • 3.6.5 Argentina
      • 3.6.6 Colombia
    • 3.7 Middle East and Africa Flu RNA Vaccines Market Facts & Figures by Country
      • 3.7.1 Middle East and Africa Flu RNA Vaccines Sales by Country
      • 3.7.2 Middle East and Africa Flu RNA Vaccines Revenue by Country
      • 3.7.3 Turkey
      • 3.7.4 Saudi Arabia
      • 3.7.5 UAE

    4 Global Flu RNA Vaccines Historic Market Analysis by Type

    • 4.1 Global Flu RNA Vaccines Sales Market Share by Type (2017-2022)
    • 4.2 Global Flu RNA Vaccines Revenue Market Share by Type (2017-2022)
    • 4.3 Global Flu RNA Vaccines Price by Type (2017-2022)

    5 Global Flu RNA Vaccines Historic Market Analysis by Application

    • 5.1 Global Flu RNA Vaccines Sales Market Share by Application (2017-2022)
    • 5.2 Global Flu RNA Vaccines Revenue Market Share by Application (2017-2022)
    • 5.3 Global Flu RNA Vaccines Price by Application (2017-2022)

    6 Key Companies Profiled

    • 6.1 Sanofi Pasteur Inc.
      • 6.1.1 Sanofi Pasteur Inc. Corporation Information
      • 6.1.2 Sanofi Pasteur Inc. Description and Business Overview
      • 6.1.3 Sanofi Pasteur Inc. Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
      • 6.1.4 Sanofi Pasteur Inc. Flu RNA Vaccines Product Portfolio
      • 6.1.5 Sanofi Pasteur Inc. Recent Developments/Updates
    • 6.2 AstraZeneca
      • 6.2.1 AstraZeneca Corporation Information
      • 6.2.2 AstraZeneca Description and Business Overview
      • 6.2.3 AstraZeneca Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
      • 6.2.4 AstraZeneca Flu RNA Vaccines Product Portfolio
      • 6.2.5 AstraZeneca Recent Developments/Updates
    • 6.3 CSL Ltd.
      • 6.3.1 CSL Ltd. Corporation Information
      • 6.3.2 CSL Ltd. Description and Business Overview
      • 6.3.3 CSL Ltd. Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
      • 6.3.4 CSL Ltd. Flu RNA Vaccines Product Portfolio
      • 6.3.5 CSL Ltd. Recent Developments/Updates
    • 6.4 Abbott
      • 6.4.1 Abbott Corporation Information
      • 6.4.2 Abbott Description and Business Overview
      • 6.4.3 Abbott Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
      • 6.4.4 Abbott Flu RNA Vaccines Product Portfolio
      • 6.4.5 Abbott Recent Developments/Updates
    • 6.5 GlaxoSmithKline Plc.
      • 6.5.1 GlaxoSmithKline Plc. Corporation Information
      • 6.5.2 GlaxoSmithKline Plc. Description and Business Overview
      • 6.5.3 GlaxoSmithKline Plc. Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
      • 6.5.4 GlaxoSmithKline Plc. Flu RNA Vaccines Product Portfolio
      • 6.5.5 GlaxoSmithKline Plc. Recent Developments/Updates
    • 6.6 Serum Institute of India Pvt. Ltd.
      • 6.6.1 Serum Institute of India Pvt. Ltd. Corporation Information
      • 6.6.2 Serum Institute of India Pvt. Ltd. Description and Business Overview
      • 6.6.3 Serum Institute of India Pvt. Ltd. Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
      • 6.6.4 Serum Institute of India Pvt. Ltd. Flu RNA Vaccines Product Portfolio
      • 6.6.5 Serum Institute of India Pvt. Ltd. Recent Developments/Updates
    • 6.7 Pfizer
      • 6.6.1 Pfizer Corporation Information
      • 6.6.2 Pfizer Description and Business Overview
      • 6.6.3 Pfizer Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
      • 6.4.4 Pfizer Flu RNA Vaccines Product Portfolio
      • 6.7.5 Pfizer Recent Developments/Updates
    • 6.8 BioNTech
      • 6.8.1 BioNTech Corporation Information
      • 6.8.2 BioNTech Description and Business Overview
      • 6.8.3 BioNTech Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
      • 6.8.4 BioNTech Flu RNA Vaccines Product Portfolio
      • 6.8.5 BioNTech Recent Developments/Updates
    • 6.9 F.Hoffman La Roche Ltd
      • 6.9.1 F.Hoffman La Roche Ltd Corporation Information
      • 6.9.2 F.Hoffman La Roche Ltd Description and Business Overview
      • 6.9.3 F.Hoffman La Roche Ltd Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
      • 6.9.4 F.Hoffman La Roche Ltd Flu RNA Vaccines Product Portfolio
      • 6.9.5 F.Hoffman La Roche Ltd Recent Developments/Updates
    • 6.10 Novartis
      • 6.10.1 Novartis Corporation Information
      • 6.10.2 Novartis Description and Business Overview
      • 6.10.3 Novartis Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
      • 6.10.4 Novartis Flu RNA Vaccines Product Portfolio
      • 6.10.5 Novartis Recent Developments/Updates
    • 6.11 Sinnovac Biotech Ltd
      • 6.11.1 Sinnovac Biotech Ltd Corporation Information
      • 6.11.2 Sinnovac Biotech Ltd Flu RNA Vaccines Description and Business Overview
      • 6.11.3 Sinnovac Biotech Ltd Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
      • 6.11.4 Sinnovac Biotech Ltd Flu RNA Vaccines Product Portfolio
      • 6.11.5 Sinnovac Biotech Ltd Recent Developments/Updates
    • 6.12 Moderna Therapeutics
      • 6.12.1 Moderna Therapeutics Corporation Information
      • 6.12.2 Moderna Therapeutics Flu RNA Vaccines Description and Business Overview
      • 6.12.3 Moderna Therapeutics Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
      • 6.12.4 Moderna Therapeutics Flu RNA Vaccines Product Portfolio
      • 6.12.5 Moderna Therapeutics Recent Developments/Updates
    • 6.13 CureVac
      • 6.13.1 CureVac Corporation Information
      • 6.13.2 CureVac Flu RNA Vaccines Description and Business Overview
      • 6.13.3 CureVac Flu RNA Vaccines Sales, Revenue and Gross Margin (2017-2022)
      • 6.13.4 CureVac Flu RNA Vaccines Product Portfolio
      • 6.13.5 CureVac Recent Developments/Updates

    7 Flu RNA Vaccines Manufacturing Cost Analysis

    • 7.1 Flu RNA Vaccines Key Raw Materials Analysis
      • 7.1.1 Key Raw Materials
      • 7.1.2 Key Suppliers of Raw Materials
    • 7.2 Proportion of Manufacturing Cost Structure
    • 7.3 Manufacturing Process Analysis of Flu RNA Vaccines
    • 7.4 Flu RNA Vaccines Industrial Chain Analysis

    8 Marketing Channel, Distributors and Customers

    • 8.1 Marketing Channel
    • 8.2 Flu RNA Vaccines Distributors List
    • 8.3 Flu RNA Vaccines Customers

    9 Flu RNA Vaccines Market Dynamics

    • 9.1 Flu RNA Vaccines Industry Trends
    • 9.2 Flu RNA Vaccines Market Drivers
    • 9.3 Flu RNA Vaccines Market Challenges
    • 9.4 Flu RNA Vaccines Market Restraints

    10 Global Market Forecast

    • 10.1 Flu RNA Vaccines Market Estimates and Projections by Type
      • 10.1.1 Global Forecasted Sales of Flu RNA Vaccines by Type (2023-2028)
      • 10.1.2 Global Forecasted Revenue of Flu RNA Vaccines by Type (2023-2028)
    • 10.2 Flu RNA Vaccines Market Estimates and Projections by Application
      • 10.2.1 Global Forecasted Sales of Flu RNA Vaccines by Application (2023-2028)
      • 10.2.2 Global Forecasted Revenue of Flu RNA Vaccines by Application (2023-2028)
    • 10.3 Flu RNA Vaccines Market Estimates and Projections by Region
      • 10.3.1 Global Forecasted Sales of Flu RNA Vaccines by Region (2023-2028)
      • 10.3.2 Global Forecasted Revenue of Flu RNA Vaccines by Region (2023-2028)

    11 Research Finding and Conclusion

      12 Methodology and Data Source

      • 12.1 Methodology/Research Approach
        • 12.1.1 Research Programs/Design
        • 12.1.2 Market Size Estimation
        • 12.1.3 Market Breakdown and Data Triangulation
      • 12.2 Data Source
        • 12.2.1 Secondary Sources
        • 12.2.2 Primary Sources
      • 12.3 Author List

      Summary:
      Get latest Market Research Reports on Flu RNA Vaccines. Industry analysis & Market Report on Flu RNA Vaccines is a syndicated market report, published as Global Flu RNA Vaccines Market Research Report 2022. It is complete Research Study and Industry Analysis of Flu RNA Vaccines market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $2,900.00
      $5,800.00
      2,296.80
      4,593.60
      2,679.60
      5,359.20
      438,741.00
      877,482.00
      241,773.00
      483,546.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report